PSNL
AI MemoPost-earnings T+3Personalis
As of 2026-08-14/Post-earnings T+3/Confidence high
Data freshness
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
high
Horizon
—
Key catalyst
Q2 clinical and reimbursement acceleration • 2026-08-04
Base target: $15 / p=40% prob
Biggest risk
The deal creates a closing and consideration risk, while Personalis remains loss-making and has limited analyst coverage. Population-sequencing revenue declined 9% year over year, and no reliable post-print analyst revision set is available in the packet.
Invalidation
Break below $12 or thesis failure.
What would change my mind?
The Q2 print supports a strengthening commercial trajectory: clinical volume, clinical revenue, Medicare coverage, and physician adoption all improved materially. The Tempus transaction also provides a potential near-term value reference at $16.25 per share.
Research note
Recommendation
—
Confidence
high
As of
2026-08-14
Base target
$15
p=40%
Bull target
$16
p=45%
Bear target
$12
p=15%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- MRD adoption and further reimbursement expansion
- The Q2 print supports a strengthening commercial trajectory: clinical volume, clinical revenue, Medicare coverage, and physician adoption all improved materially.
- The Tempus transaction also provides a potential near-term value reference at $16.25 per share.
BearKey bullets
- Clinical growth depends on reimbursement expansion, physician adoption, and continued evidence generation.
- Insider Form 4 activity included open-market sales by senior officers; this is a sentiment and alignment risk, not evidence of operating deterioration.
- [#SEC-FORM4-2026-07-15] [#SEC-FORM4-2026-07-09]
WatchKey bullets
- Q2 clinical and reimbursement acceleration
Summary
High-level snapshot
Recommendation
-
Model confidence
high
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+3
Base case: $15 (p=40%)
Target spread vs base: +7% / -25%
Scenario probabilities
Bull Target: $16 (p=45%)Base Target: $15 (p=40%)Bear Target: $12 (p=15%)
Commentary
News tone is positive because of the Tempus acquisition, strong Q2 clinical growth, and expanded Medicare coverage, but confidence is moderated by low coverage and missing social, options, short-interest, and post-print analyst data. The queue labels an August 11 earnings date, while the available company/SEC earnings release is dated August 4; no separate August 11 company release or transcript is included. The memo therefore remains a cautious, deal-supported monitoring view rather than a high-conviction standalone valuation call.
As of 2026-08-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
The Q2 print supports a strengthening commercial trajectory: clinical volume, clinical revenue, Medicare coverage, and physician adoption all improved materially. The Tempus transaction also provides a potential near-term value reference at $16.25 per share.
Bear Case
The deal creates a closing and consideration risk, while Personalis remains loss-making and has limited analyst coverage. Population-sequencing revenue declined 9% year over year, and no reliable post-print analyst revision set is available in the packet.
Drivers
Scannable catalysts and supporting factors
- MRD adoption and further reimbursement expansion
Scenarios
Bull Target (Scenario probability)
$16 / p=45% prob
Base Target (Scenario probability)
$15 / p=40% prob
Bear Target (Scenario probability)
$12 / p=15% prob
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
72.00
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-08-04Q2 clinical and reimbursement accelerationQ2 revenue rose 30% year over year to $22.4 million, clinical revenue rose 442% to $2.6 million, and clinical test volume rose 199% to 10,384. Medicare coverage expanded NeXT Personal to four indications. [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-04]Prob 85.00% • Move 5.00% • Priced-in 80.00%
- EVENT2026-11-12Tempus acquisition spread resolutionTempus agreed to acquire Personalis for stated consideration of $16.25 per share, implying roughly 12.7% upside from the $14.42 anchor price, subject to transaction-closing conditions and Tempus-stock exposure. [#SEC-8K-2026-07-20]Prob 75.00% • Move 12.70% • Priced-in 80.00%
Short-term Catalysts
Next few weeks
No short-term catalysts
Long-term Catalysts
Months to a year
- MRD adoption and further reimbursement expansion2027-08-14More than 1,400 physicians were ordering NeXT Personal, while management cited ongoing evidence generation to support reimbursement expansion into additional indications. Execution remains the key uncertainty. [#PR-EARNINGS-2026-08-04]Prob 60% • Move 15% • Priced-in 55%
Risks
- Clinical growth depends on reimbursement expansion, physician adoption, and continued evidence generation.
- Insider Form 4 activity included open-market sales by senior officers; this is a sentiment and alignment risk, not evidence of operating deterioration. [#SEC-FORM4-2026-07-15] [#SEC-FORM4-2026-07-09]
- Population-sequencing revenue declined 9% year over year in Q2. [#SEC-8K-2026-08-04]
- Tempus transaction may be delayed, terminated, or affected by approval, shareholder, integration, or Tempus-share-price conditions. [#SEC-8K-2026-07-20]
- The company reported a Q2 net loss of $31.7 million, leaving execution and cash-burn discipline important despite approximately $212.7 million of cash, cash equivalents, and short-term investments. [#PR-EARNINGS-2026-08-04]
- The packet does not provide dependable post-print analyst revisions, options data, short interest, or a verified post-release market-reaction attribution.
Peers
| Symbol | Summary |
|---|---|
| BCAX | Same-sector and similar-market-cap candidate, but not a direct MRD diagnostic comparable; comparison confidence is low. |
| MAZE | Same-sector and similar-market-cap clinical-stage biotech candidate, with limited comparability to Personalis's commercial precision-oncology diagnostics. |
| TRAX | Similar-market-cap life-sciences candidate, but the peer relationship is loose and not suitable for precise valuation benchmarking. |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-08-14